Necrotizing myopathy (NM) can also be referred to as necrotizing autoimmune myopathy (NAM) or immune-mediated necrotizing myopathy (IMNM). The condition is characterized by signs of necrosis, or cell death, in the muscles, which causes muscle weakness. As with other types of myositis, there is no known cause or cure for necrotizing myopathy. However, treatments are available that can successfully manage symptoms.
Signs and symptoms
Those with necrotizing myopathy may experience the following symptoms:
- Weakness in the muscles closest to the center of the body, like the shoulders, forearms, hips, thighs, neck, and back
- Difficulty climbing stairs and standing up from a chair
- Difficulty lifting arms over the head
- Falling and difficulty getting up from a fall
- Shortness of breath and/or chronic dry cough
- Difficulty swallowing (dysphagia)
Disassociated from polymyositis
Necrotizing myopathy is a distinct subset of idiopathic inflammatory myopathy, or myositis. Patients with necrotizing myopathy have muscle biopsies characterized by predominant necrosis (i.e., death) of muscle cells with often less inflammation than other myositis subsets.
Before necrotizing myopathy was recognized as a separate entity, many patients with necrotizing myopathies were labelled as polymyositis, because both subsets share similar clinical features. However, specific autoantibodies (for example, anti-HMGCR) and muscle biopsy features can help physicians differentiate those diseases.
Categories of necrotizing myopathies
There are different categories of necrotizing myopathies characterized by distinct risk factors and disease course. These categories are mainly differentiated based on autoantibodies measured in the patient’s blood.
Patients with anti-SRP autoantibodies
Anti-signal recognition particle (SRP) autoantibodies are found in some patients with necrotizing myopathies. Their presence are often associated with severe muscle weakness and difficulty swallowing. Inflammation of the lungs and heart can also be seen in that subset.
Patients with anti-HMGCR autoantibodies
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) is a key enzyme in the production of cholesterol. Some patients exposed to HMGCR inhibitors for cholesterol treatment (that is, statins) or through dietary sources (for example, red yeast rice and oyster mushrooms) can develop anti-HMGCR autoantibodies. Sometimes, however, no environmental triggers are found to explain their presence. Anti-HMGCR positive necrotizing myopathies usually present with mainly severe muscle symptoms.
Patients with no autoantibodies
Patients with necrotizing myopathies without anti-SRP or -HMGCR autoantibodies in their blood are considered by some experts to be included in a separate, third grouping of necrotizing myopathies called seronegative.
If you are experiencing muscle symptoms involving weakness or fatigue, we encourage you to talk to your doctor to begin the diagnosis process, which includes a muscle biopsy to detect necrosis and various blood tests to detect the presence of autoantibodies. Since necrotizing myopathy is a rare disease, many physicians may not be familiar with the signs and symptoms. If you are struggling to find an accurate diagnosis, visiting a specialist can help.
Revised April 2025 by Valérie Leclair, MD, PhD – rheumatologist, research scientist, and TMA medical advisor